In addition, FXR‐α activity was shown to suppress NF‐κB agonist‐induced inflammatory gene expression in an FXR‐α‐dependent manner in HepG2 cells and mouse primary hepatocytes60 as well as CRP release,61 suggesting that blocking IL‐1R1 in hepatocytes prevents dysregulation of both PGC‐1α and FXR‐α in NAFLD. This evidence concerns the gene PPARGC1A and metabolic dysfunction-associated steatotic liver disease.